McKesson - MCK Stock Forecast, Price & News

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, International, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS). The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs and other healthcare-related products. This segment also provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices; and consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies. The International segment offers distribution and services to wholesale, institutional, and retail customers in 13 European countries and Canada. The Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers. The RxTS segment serves biopharma and life sciences partners and patients to address medication challenges for patients throughout their journeys; connects pharmacies, providers, payers, and biopharma companies to deliver innovative access and adherence solutions; and provides third-party logistics and wholesale distribution support solutions. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.

McKesson Price Performance

Shares of McKesson stock opened at $367.37 on Thursday. The stock's 50-day moving average is $330.54 and its 200 day moving average is $312.34. The firm has a market cap of $52.80 billion, a price-to-earnings ratio of 38.83, a PEG ratio of 1.53 and a beta of 0.63. McKesson has a one year low of $193.89 and a one year high of $375.23.

McKesson Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, October 3rd. Investors of record on Thursday, September 1st will be given a dividend of $0.54 per share. This is a boost from McKesson's previous quarterly dividend of $0.47. The ex-dividend date is Wednesday, August 31st. This represents a $2.16 annualized dividend and a dividend yield of 0.59%. McKesson's payout ratio is presently 19.87%.

Wall Street Analyst Weigh In

Several analysts have issued reports on MCK shares. Argus cut McKesson from a "buy" rating to a "hold" rating in a research note on Wednesday, July 6th. Deutsche Bank Aktiengesellschaft upped their target price on McKesson from $378.00 to $409.00 in a research report on Monday, August 8th. Cowen increased their target price on shares of McKesson to $384.00 in a research note on Tuesday, August 9th. Credit Suisse Group boosted their price target on shares of McKesson from $377.00 to $385.00 and gave the company an "outperform" rating in a report on Monday, August 8th. Finally, Mizuho upped their price objective on shares of McKesson from $331.00 to $345.00 and gave the company a "neutral" rating in a research note on Thursday, August 4th. Two analysts have rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, McKesson has an average rating of "Moderate Buy" and a consensus target price of $337.62.

Insider Activity at McKesson

In other news, CEO Brian S. Tyler sold 1,535 shares of the stock in a transaction that occurred on Tuesday, June 21st. The shares were sold at an average price of $305.20, for a total transaction of $468,482.00. Following the completion of the transaction, the chief executive officer now directly owns 75,737 shares of the company's stock, valued at approximately $23,114,932.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other McKesson news, CEO Brian S. Tyler sold 1,535 shares of the business's stock in a transaction that occurred on Tuesday, June 21st. The shares were sold at an average price of $305.20, for a total value of $468,482.00. Following the completion of the transaction, the chief executive officer now owns 75,737 shares of the company's stock, valued at approximately $23,114,932.40. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CFO Britt J. Vitalone sold 27,281 shares of the firm's stock in a transaction that occurred on Friday, May 27th. The stock was sold at an average price of $333.16, for a total value of $9,088,937.96. Following the transaction, the chief financial officer now owns 13,693 shares in the company, valued at $4,561,959.88. The disclosure for this sale can be found here. Insiders have sold 44,396 shares of company stock valued at $14,471,365 over the last ninety days. Corporate insiders own 0.21% of the company's stock.